Division of Molecular Medicine, Children's Hospital, Boston, MA 02115, USA.
Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):12111-6. doi: 10.1073/pnas.1204533109. Epub 2012 Jul 5.
HIV-1 envelope glycoprotein is the primary target for HIV-1-specific antibodies. The native HIV-1 envelope spike on the virion surface is a trimer, but trimeric gp140 and monomeric gp120 currently are believed to induce comparable immune responses. Indeed, most studies on the immunogenicity of HIV-1 envelope oligomers have revealed only marginal improvement over monomers. We report here that suitably prepared envelope trimers have nearly all the antigenic properties expected for native viral spikes. These stable, rigorously homogenous trimers have antigenic properties markedly different from those of monomeric gp120s derived from the same sequences, and they induce potent neutralizing antibody responses for a cross-clade set of tier 1 and tier 2 viruses with titers substantially higher than those elicited by the corresponding gp120 monomers. These results, which demonstrate that there are relevant immunologic differences between monomers and high-quality envelope trimers, have important implications for HIV-1 vaccine development.
HIV-1 包膜糖蛋白是 HIV-1 特异性抗体的主要靶标。病毒表面上天然的 HIV-1 包膜刺突是三聚体,但目前认为三聚体 gp140 和单体 gp120 可诱导相当的免疫反应。事实上,大多数关于 HIV-1 包膜寡聚体免疫原性的研究仅显示出与单体相比略有改善。我们在此报告称,经过适当制备的包膜三聚体具有几乎所有预期的天然病毒刺突的抗原特性。这些稳定、严格同质的三聚体具有与源自相同序列的单体 gp120 明显不同的抗原特性,并且它们诱导针对跨群 1 和 2 级病毒的强效中和抗体反应,其滴度明显高于相应 gp120 单体引起的滴度。这些结果表明单体和高质量包膜三聚体之间存在相关的免疫学差异,对 HIV-1 疫苗的开发具有重要意义。